Abstract
Introduction To better identify illnesses with severe hypoxemia in children aged under-5 years, the AIRE project has implemented the routine use of a Pulse Oximeter (PO) into the Integrated Management of Childhood Illness (IMCI) guidelines at primary health centers (PHC) in Burkina Faso, Guinea, Mali, and Niger. We aimed to measure and understand the acceptability among healthcare workers (HCW) and children’s families (CF) of using PO in these contexts.
Methods Based on an original conceptual framework, we conducted a convergent mixed methods study to assess HCW’s and CF’s acceptability. We used quantitative questionnaires based on the Likert scale to conduct four repeated cross-sectional studies among all HCW on duty in the 202 PHC involved in the AIRE project before the intervention (before and after PO use training), six months after the introduction of the PO, and two months after project completion. We also conducted semi-structured interviews with HCW (n=102) and CF (n=59).
Results From March 2021 to December 2022, 486, 537, 538 and 476 HCW completed the four acceptability surveys. Overall, 31% of HCW had mitigated feelings about PO use before the training, 46% found it rather acceptable and 23% strongly acceptable. At the end of the project, it was respectively 15%, 34% and 51%. PO training was consistently associated with greater HCW acceptability. HCW found many advantages in using PO, such as improved care for children, more accurate diagnosis, and a boost in their confidence in childcare management. Nevertheless, perceived increased workload and consultation time, as well as difficulties in referring children to hospital remain challenging. CF did not necessarily understand the new device’s purpose, but their opinions of the technology were generally positive.
Conclusion The PO use, integrated into IMCI consultations, seems to be accepted by HCW and CF, although sustainable challenges remain.
What is already known on this topic
Even if PO effectiveness is well-known, integration of new medical technologies in primary health care settings in low-resource countries often faces challenges, including acceptability among healthcare workers and families.
Previous studies that have looked at the acceptability of PO were mostly hospital-based and did not use a comprehensive methodology to investigate acceptability in depth.
What this study adds
To our knowledge, this is the first study to examine the acceptability of a healthcare innovation to HCW and CF, based on a comprehensive theoretical framework, combining a quantitative and qualitative approach, and using an innovative acceptability score.
This study provides empirical evidence on the high acceptability of PO use for HCW and CF at a decentralized level in Burkina Faso, Guinea, Mali, and Niger.
Training and supervision significantly improved HCW acceptability of PO use, with increased confidence in childcare management. However, challenges such as increased workload and consultation time, as well as referral difficulties, persist despite the overall positive opinion.
How this study might affect research, practice or policy
The findings support the need for comprehensive training and supervision programs to enhance acceptability among HCW.
Policymakers should work towards addressing the operational challenges identified, especially those related to the referral of children, which could hinder the sustainability of PO use.
Research aiming to evaluate acceptability should be based on conceptual frameworks or theories that allow for an in-depth exploration of the different dimensions of acceptability.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PACTR202206525204526
Clinical Protocols
https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-08982-4
Funding Statement
The AIRE project is funded by UNITAID, with in-kind support from Inserm and IRD. UNITAID was not involved in the design of the study, the collection, analysis and interpretation of the data, nor in the writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
- The WHO Ethics Review Committee (WHO-ERC) gave ethical approval for this work (ERC.0003364) - The Inserm Institutional Evaluation Ethics Committee (IEEC) gave ethical approval for this work (Inserm IEEC 20-720). - The "Comite d Ethique pour la Recherche en Sante (CERS), of Burkina Faso gave ethical approval for this work (2020-4-070). - The "Comite National d Ethique pour la Recherche en Sante (CNERS)", of Guinea gave ethical approval for this work (169/CNERS/21). - The "Comite National d Ethique pour la Sante et les Sciences de la vie (CNESS)", of Mali gave ethical approval for this work (127/MSDS-CNESS). - The "Comite National d Ethique pour la Recherche en Sante (CNERS)", of Niger gave ethical approval for this work (67/2020/CNERS).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes